98%
921
2 minutes
20
Background: Understanding emergency department and healthcare utilisation related to acute recreational drug toxicity (ARDT) generally relies on nationally collated data based on ICD-10 coding. Previous UK studies have shown this poorly captures the true ARDT burden. The aim of this study was to investigate whether this is also the case elsewhere in Europe.
Methods: The Euro-DEN Plus database was interrogated for all presentations 1st July to 31st December 2015 to the EDs in (i) St Thomas' Hospital, London, UK; (ii) Universitätsspital Basel, Basel, Switzerland; and (iii) Zealand University Hospital, Roskilde, Denmark. Comparison of the drug(s) involved in the presentation with the ICD-10 codes applied to those presentations was undertaken to determine the proportion of cases where the primary/subsequent ICD-10 code(s) were ARDT related.
Results: There were 619 presentations over the 6-month period. Two hundred thirteen (34.4%) of those presentations were coded; 89.7% had a primary/subsequent ARDT-related ICD-10 code. One hundred percent of presentations to Roskilde had a primary ARDT ICD-10 code compared to 9.6% and 18.9% in Basel and London respectively. Overall, only 8.5% of the coded presentations had codes that captured all of the drugs that were involved in that presentation.
Conclusions: While the majority of primary and secondary codes applied related to ARDT, often they did not identify the actual drug(s) involved. This was due to both inconsistencies in the ICD-10 codes applied and lack of ICD-10 codes for the drugs/NPS. Further work and education is needed to improve consistency of use of current ICD-10 and future potential ICD-11 coding systems.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440929 | PMC |
http://dx.doi.org/10.1007/s13181-018-0687-z | DOI Listing |
Pharmacoepidemiol Drug Saf
September 2025
Sanofi, Cambridge, Massachusetts, USA.
Purpose: Given the increased likelihood for individuals with severe asthma to experience comorbidities, disease complications, emergency room visits, and hospitalizations, the ability to stratify asthma populations on severity is often important. Although pharmacoepidemiologic studies using administrative healthcare databases sometimes categorize asthma severity, there is no consensus on an approach.
Methods: Individuals with asthma (≥ 2 ICD-10-CM diagnosis codes J45) aged ≥ 6 years were identified in Optum's de-identified Clinformatics Data Mart Database between January 2017 and November 2023.
Clin Pharmacol Ther
September 2025
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
This study aimed to assess the ability of two off-the-shelf large language models, ChatGPT and Gemini, to support the design of pharmacoepidemiological studies. We assessed 48 study protocols of pharmacoepidemiological studies published between 2018 and 2024, covering various study types, including disease epidemiology, drug utilization, safety, and effectiveness. The coherence (i.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Section of Surgical Oncology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Background: Postmastectomy autologous reconstruction (PMAR) is an important component of comprehensive breast cancer care. Previous research has suggested the existence of sociodemographic disparities in complications after immediate PMAR. The objective of this study was to examine the impact of sociodemographic and clinical factors on immediate PMAR postoperative outcomes.
View Article and Find Full Text PDFMod Rheumatol
September 2025
Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan.
ObjectivesThe 2023 EULAR guidelines for systemic sclerosis (SSc) newly recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD). This study investigated recent actual use of these drugs in Japan. MethodsWe analysed data from a Japanese hospital claims database (2020-2023), identifying patients with SSc disease codes (ICD-10 M34.
View Article and Find Full Text PDFCureus
August 2025
Department of Health Sciences, University of Jamestown, Fargo, USA.
Background Heart failure (HF) is a leading cause of morbidity and hospitalization, encompassing distinct phenotypes: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Disparities in diagnostic imaging may contribute to underdiagnosis and unequal care. This study evaluates differences in combined diagnostic imaging utilization between HFpEF and HFrEF, focusing on social determinants of health (SDoH) and hospital region.
View Article and Find Full Text PDF